Guardant Health, Inc.
For the period ended Sep 30, 2026. Filed Nov 5, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 5, 2026
GH$158.79+5.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(in thousands, except share and per share data)
| September 30, 2026 | December 31, 2025 | |
|---|---|---|
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $1,026,848 | $378,203 |
| Short-term marketable securities | — | 823,395 |
| Accounts receivable, net | 186,548 | 137,849 |
| Inventory, net | 93,490 | 85,876 |
| Prepaid expenses and other current assets | 36,519 | 40,723 |
| Total current assets | 1,343,405 | 1,466,046 |
| Restricted cash | 119,157 | 111,214 |
| Property and equipment, net | 151,474 | 145,915 |
| Right-of-use assets | 141,245 | 158,849 |
| Intangible assets, net | 24,988 | 25,921 |
| Goodwill | 77,257 | 77,257 |
| Other assets, net | 28,116 | 28,457 |
| Total assets | $1,885,642 | $2,013,659 |
| LIABILITIES AND STOCKHOLDERS’ DEFICIT | ||
| Current liabilities: | ||
| Accounts payable | $102,512 | $54,442 |
| Accrued compensation | 127,619 | 119,646 |
| Accrued expenses | 104,935 | 77,889 |
| Deferred revenue | 38,099 | 50,753 |
| Total current liabilities | 373,165 | 302,730 |
| Convertible senior notes, net | 1,502,413 | 1,504,000 |
| Long-term operating lease liabilities | 160,220 | 178,463 |
| Other long-term liabilities | 125,746 | 127,773 |
| Total liabilities | 2,161,544 | 2,112,966 |
| Commitments and contingencies (Note 9) | ||
| Stockholders’ deficit: | ||
| Preferred stock, par value of $0.00001 per share; 10,000,000 shares authorized, no shares issued and outstanding as of September 30, 2026 and December 31, 2025 | — | — |
| Common stock, par value of $0.00001 per share; 350,000,000 shares authorized; 134,719,874 and 130,635,301 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively | 1 | 1 |
| Additional paid-in capital | 3,080,321 | 2,900,056 |
| Accumulated other comprehensive loss | (5,133) | (4,852) |
| Accumulated deficit | (3,351,091) | (2,994,512) |
| Total stockholders’ deficit | (275,902) | (99,307) |
| Total liabilities and stockholders’ deficit | $1,885,642 | $2,013,659 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.